Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

1,001

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

March 21, 2023

Study Completion Date

March 24, 2023

Conditions
Helminthes; Infestation, Intestinal
Interventions
COMBINATION_PRODUCT

Albendazole and Ivermectin fixed dose coformulation

400 mg Albendazole - 9 mg Ivermectin OR 400 mg Albendazole - 18 mg Ivermectin

DRUG

Albendazole

Albendazole 400mg single dose

Trial Locations (3)

1929

Centro de Investigação em Saúde da Manhiça (CISM), Manhiça

P.O. Box 79

Bahir Dar University, Colleges of Medicine and Health Sciences (BDU-CMHS), Bahir Dar

54840-00200

Kenya Medical Research Institute (KEMRI), Nairobi

All Listed Sponsors
collaborator

Leiden University Medical Center

OTHER

collaborator

Bahir Dar University

OTHER

collaborator

Centro de Investigacao em Saude de Manhica

OTHER

collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

Kenya Medical Research Institute

OTHER

collaborator

Laboratorios Liconsa

INDUSTRY

collaborator

Universidad de León

OTHER

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

Barcelona Institute for Global Health

OTHER